In the News: Potential Approval of Gene Therapy Drug New gene therapy, maybe 1st of its kind approved by the US FDA, will be used to treat patients ages 3 to 25 that have been diagnosed with B-cell acute lymphoblastic leukemia (ALL). A new drug may provide hope for the families of children that have been diagnosed with B-cell acute lymphoblastic leukemia (ALL), the most common form childhood cancer in the United States. According to a report from Reuters, the U.S. Food and Drug Administration is one-step away from the approval of the drug, tisagenlecleucel for patients’ ages 3 to 25 who have -cell acute lymphoblastic leukemia after a review panel unanimously recommended its approval. The drug tisagenlecleucel was pioneered by Novartis AG uses the CRISPR technology (we discussed in our previous blog) along with another new technology known as CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's own immune cells to recognize and attack malignant cells. The new drug is expected to be granted approval by the FDA later this week.
0 comments on "In the News: Potential Approval of Gene Therapy Drug"